<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>2017 European LeukemiaNet risk stratification of acute myeloid leukemia by genetics</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">2017 European LeukemiaNet risk stratification of acute myeloid leukemia by genetics</h1>
<div class="graphic"><div class="figure"><div class="ttl">2017 European LeukemiaNet risk stratification of acute myeloid leukemia by genetics</div><div class="cntnt"><table cellspacing="0"><colgroup width="30%"></colgroup><colgroup width="70%"></colgroup> <tbody> <tr> <td class="subtitle1">Risk category*</td> <td class="subtitle1">Genetic abnormality</td> </tr> <tr> <td class="divider_bottom" rowspan="4"><strong>Favorable</strong></td> <td>t(8;21)(q22;q22.1); <em>RUNX1-RUNX1T1</em></td> </tr> <tr> <td>inv(16)(p13.1;q22) or t(16;16)(p13.1;q22); <em>CBFB-MYH11</em></td> </tr> <tr> <td>Mutated <em>NPM1</em> without <em>FLT3-ITD</em> or with <em>FLT3-ITD</em><sup>low</sup><sup>¶</sup></td> </tr> <tr class="divider_bottom"> <td>Biallelic mutated <em>CEBPA</em></td> </tr> <tr> <td class="divider_bottom" rowspan="4"><strong>Intermediate</strong></td> <td>Mutated <em>NPM1</em> and <em>FLT3-ITD</em><sup>high</sup><sup>¶</sup></td> </tr> <tr> <td>Wild type <em>NPM1</em> without <em>FLT3-ITD</em> or with <em>FLT3-ITD</em><sup>low</sup><sup>¶</sup> (without adverse-risk genetic lesions)</td> </tr> <tr> <td>t(9;11)(p21.3;q23.3); <em>MLLT3-KMT2A</em><sup>Δ</sup></td> </tr> <tr class="divider_bottom"> <td>Cytogenetic abnormalities not classified as favorable or adverse</td> </tr> <tr> <td rowspan="9"><strong>Adverse</strong></td> <td>t(6;9)(p23;q34.1); <em>DEK-NUP214</em></td> </tr> <tr> <td>t(v;11q23.3); <em>KMT2A</em> rearranged</td> </tr> <tr> <td>t(9;22)(q34.1;q11.2); <em>BCR-ABL1</em></td> </tr> <tr> <td>inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); <em>GATA2,MECOM</em>(<em>EVI1</em>) –5 or del(5q); –7; –17/abn(17p)</td> </tr> <tr> <td>Complex karyotype,<sup>◊</sup> monosomal karyotype<sup>§</sup></td> </tr> <tr> <td>Wild type <em>NPM1</em> and <em>FLT3-ITD</em><sup>high</sup><sup>¶</sup></td> </tr> <tr> <td>Mutated <em>RUNX1</em><sup>¥</sup></td> </tr> <tr> <td>Mutated <em>ASXL1</em><sup>¥</sup></td> </tr> <tr> <td>Mutated <em>TP53</em><sup>‡</sup></td> </tr> </tbody></table></div><div class="graphic_lgnd">This table describes the European LeukemiaNet stratification of acute myeloid leukemia (AML) based on cytogenetic and molecular characteristics. Note the use of "allelic ratio" to stratify based on the <em innerhtml="">FLT3</em>-ITD mutation. Various research groups calculate this ratio differently and/or use other cutoff values.</div><div class="graphic_footnotes">* Prognostic impact of a marker is treatment-dependent and may change with new therapies.<br/>¶ Low, low allelic ratio (&lt;0.5); high, high allelic ratio (&gt;0.5); semi-quantitative assessment of <em>FLT3-ITD</em> allelic ratio (using DNA fragment analysis) is determined as ratio of the area under the curve (AUC) "<em>FLT3-ITD</em>" divided by AUC "<em>FLT3</em>-wild type"; recent studies indicate that acute myeloid leukemia with <em>NPM1</em> mutation and <em>FLT3-ITD</em> low allelic ratio may also have a more favorable prognosis and patients should not routinely be assigned to allogeneic hematopoietic-cell transplantation.<sup>[1-4]</sup><br/>Δ The presence of t(9;11)(p21.3;q23.3) takes precedence over rare, concurrent adverse-risk gene mutations.<br/><font class="lozenge">◊</font> Three or more unrelated chromosome abnormalities in the absence of one of the World Health Organization-designated recurring translocations or inversions, ie, t(8;21), inv(16) or t(16;16), t(9;11), t(v;11)(v;q23.3), t(6;9), inv(3) or t(3;3); AML with <em>BCR-ABL1</em>.<br/>§ Defined by the presence of one single monosomy (excluding loss of X or Y) in association with at least one additional monosomy or structural chromosome abnormality (excluding core-binding factor AML).<sup>[5]</sup><br/>¥ These markers should not be used as an adverse prognostic marker if they co-occur with favorable-risk AML subtypes.<br/>‡ <em>TP53</em> mutations are significantly associated with AML with complex and monosomal karyotype.<sup>[6-10]</sup></div><div class="graphic_reference">References: 

<ol>
<li>Gale RE, Green C, Allen C, et al; Medical Research Council Adult Leukaemia Working Party. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 2008; 111:2776.</li>
<li>Pratcorona M, Brunet S, Nomdedéu J, et al. Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to postremission therapy. Blood 2013; 121:2734.</li>
<li>Schlenk RF, Kayser S, Bullinger L, et al. Differential impact of allelic ratio and insertion site in FLT3-ITDpositive AML with respect to allogeneic transplantation. Blood 2014; 124:3441.</li>
<li>Ho AD, Schetelig J, Bochtler T, et al. Allogeneic stem cell transplantation improves survival in patients with acute myeloid leukemia characterized by a high allelic ratio of mutant FLT3-ITD. Biol Blood Marrow Transplant 2016; 22:462.</li>
<li>Breems DA, van Putten WLJ, De Greef GE, et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol 2008; 26:4791.</li>
<li>Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 2016;374:2209.</li>
<li>Haferlach C, Dicker F, Herholz H, Schnittger S, Kern W, Haferlach T. Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype. Leukemia 2008; 22:1539.</li>
<li>Bowen D, Groves MJ, Burnett AK, et al. TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis. Leukemia 2009; 23:203.</li>
<li>Rücker FG, Schlenk RF, Bullinger L, et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood 2012; 119:2114.</li>
<li>Devillier R. Mansat-De Mas V, Gelsi-Boyet V, et al. Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes. Oncotarget 2015; 6:8388.</li></ol>Reproduced with permission of the American Society of Hematology, from: Döhner H, Estey E, Grimwade D, et al. Diagnosis and Management of AML in Adults: 2017 ELN Recommendations from an International Expert Panel. Blood 2016; permission conveyed through Copyright Clearance Center, Inc. Copyright © 2016.</div><div id="graphicVersion">Graphic 111588 Version 10.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
